Answers are grounded in this paper and cite their sources.
Intestinal dysbiosis is central to inflammatory bowel disease (IBD) development. Probiotics produce propionate, a short-chain fatty acid that restores intestinal balance and reduces inflammation. Comparative genomic analysis of propionate pathway integrity was performed to nominate 41 candidate strains. Metabolic analysis confirmed the propionate production of 9 strains of them. Caco-2/HT29-MTX-E12 confluence epithelial model was established to investigate the effect of the strains on intestinal cell. DSS-induced colitis in a mouse model was also included as an in vivo verification of the filtered probiotic strains. The methods successfully nominated 2 potential strains: Bifidobacterium breve XA-2103 and Pediococcus acidilactici GOLDGUT-PA0755. Both had a preferential ability to produce propionate and to reduce the effect on the intestinal barrier in the confluence cell model. Furthermore, their therapeutic effects were verified by reduced body weight loss, shortening of the colon length, Disease Activity Index score and improvement in histological analysis. • Screening and identification of propionate-producing probiotics for IBD therapy. • Genomic annotation and comparative genomic analysis of propionate pathway integrity to nominate candidate strains. • Verification of strains that restore intestinal barrier integrity in the Caco-2/HT29-MTX-E12 confluence epithelial monolayer cell model. • B. breve XA-2103 and P. acidilactici GOLDGUT-PA0755 modulate immune response in DSS-induced colitis model.
No takes yet. Share an insight, caveat, or question.
Shu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: